Treatment of syphilis: current recommendations, alternatives, and continuing problems

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Syphilis treatment relies heavily on Benzathine penicillin.
• Rising syphilis rates and concerns for HIV-coinfected individuals necessitate treatment reappraisal.
• Current therapies may not ensure adequate central nervous system (CNS) penetration.

Purpose of the Study:

• To evaluate current syphilis treatment options.
• To identify ideal characteristics for alternative antimicrobial agents.
• To address the need for effective and cost-efficient syphilis therapy.

Main Methods:

• Review of existing literature on benzathine penicillin, tetracycline, erythromycin, and ceftriaxone for syphilis.
• Assessment of drug properties: serum half-life, CNS penetration, and administration ease.
• Analysis of treatment efficacy, particularly for CNS involvement.

Main Results:

• Benzathine penicillin offers prolonged serum levels but inadequate CNS penetration.
• Tetracycline and erythromycin have limitations including dosing frequency, adverse effects, and unproven CNS efficacy.
• Ceftriaxone shows promise for early syphilis, but optimal dosing remains undetermined.

Conclusions:

• No single syphilis therapy is currently optimal for efficacy and cost-effectiveness.
• Reappraisal of existing and alternative treatments for syphilis is crucial.
• Further research is needed to establish reliable and safe syphilis treatment regimens.